FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800647235> ?p ?o ?g. }

• W2800647235 endingPage "1923" @default.
• W2800647235 startingPage "1914" @default.
• W2800647235 abstract "Background Current guideline recommendations for immunosuppression reduction after diagnosis of posttransplant lymphoproliferative disorder (PTLD) include stopping antimetabolites, reducing calcineurin inhibitors, and maintaining corticosteroids. However, the effect of immunosuppression on PTLD relapse risk after up-to-date therapy is unclear. Methods This is a retrospective analysis of immunosuppression, patient baseline characteristics, and relapse risk measured as landmark time to progression (TTP) starting 1 year after start of therapy in 159 patients with B cell PTLD after solid organ transplantation treated in the prospective, international, multicenter PTLD-1 trials with either sequential treatment (rituximab followed by cyclophosphamide (CHOP-21 chemotherapy) 750 mg/m 2 intravenously [IV] day (d) 1, doxorubicin 50 mg/m 2 IV d1, vincristine 1.4 mg/m 2 (maximum, 2 mg) IV d1, and prednisone 50 mg/m 2 PO d1-5, every 21 days) or risk-stratified sequential treatment (rituximab followed by rituximab or rituximab (R-CHOP-21 immunochemotherapy) 375 mg/m 2 IV day (d) 1, cyclophosphamide 750 mg/m 2 IV d1, doxorubicin 50 mg/m 2 IV d1, vincristine 1.4 mg/m 2 (max. 2 mg) IV d1, and prednisone 50 mg/m 2 PO d1-5, every 21 days). Results Patient baseline characteristics at diagnosis of PTLD differed significantly depending on immunosuppression before diagnosis. Compared with immunosuppression before diagnosis, significantly fewer patients received an antimetabolite or a calcineurin inhibitor (CNI) after diagnosis of PTLD. Relapse risk measured as landmark TTP was significantly higher for patients on corticosteroids compared to all others ( P = 0.010) as well as for patients on ciclosporin compared with those on tacrolimus ( P = 0.002), but similar for those on antimetabolites compared with all others ( P = 0.912). In a Cox regression analysis of landmark TTP, corticosteroid-containing immunosuppression after diagnosis of PTLD ( P = 0.002; hazard ratio, 11.195) and age ( P = 0.001; hazard ratio, 1.076/year) were identified as independent, significant risk factors for PTLD relapse. Conclusions In the prospective PTLD-1 trials, corticosteroid use after diagnosis of PTLD is associated with an increased risk of relapse, whereas the use of antimetabolites is not. These findings require prospective validation." @default.
• W2800647235 created "2018-05-17" @default.
• W2800647235 creator A5003069482 @default.
• W2800647235 creator A5003581995 @default.
• W2800647235 creator A5006705594 @default.
• W2800647235 creator A5014153145 @default.
• W2800647235 creator A5015917994 @default.
• W2800647235 creator A5027749653 @default.
• W2800647235 creator A5028727344 @default.
• W2800647235 creator A5033063736 @default.
• W2800647235 creator A5033841824 @default.
• W2800647235 creator A5037283048 @default.
• W2800647235 creator A5040437868 @default.
• W2800647235 creator A5046049357 @default.
• W2800647235 creator A5047984145 @default.
• W2800647235 creator A5051605599 @default.
• W2800647235 creator A5053019069 @default.
• W2800647235 creator A5058765211 @default.
• W2800647235 creator A5061694042 @default.
• W2800647235 creator A5066826766 @default.
• W2800647235 creator A5082867129 @default.
• W2800647235 creator A5084858618 @default.
• W2800647235 creator A5085255418 @default.
• W2800647235 creator A5086292280 @default.
• W2800647235 creator A5091740511 @default.
• W2800647235 date "2018-11-01" @default.
• W2800647235 modified "2023-10-07" @default.
• W2800647235 title "Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials" @default.
• W2800647235 cites W1544269146 @default.
• W2800647235 cites W1925602349 @default.
• W2800647235 cites W1989324824 @default.
• W2800647235 cites W1994080024 @default.
• W2800647235 cites W1998407875 @default.
• W2800647235 cites W2011757232 @default.
• W2800647235 cites W2015278968 @default.
• W2800647235 cites W2024382442 @default.
• W2800647235 cites W2025321012 @default.
• W2800647235 cites W2087522272 @default.
• W2800647235 cites W2091616383 @default.
• W2800647235 cites W2131598459 @default.
• W2800647235 cites W2170308172 @default.
• W2800647235 cites W2578876390 @default.
• W2800647235 cites W2606254790 @default.
• W2800647235 cites W4205736005 @default.
• W2800647235 doi "https://doi.org/10.1097/tp.0000000000002269" @default.
• W2800647235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29757894" @default.
• W2800647235 hasPublicationYear "2018" @default.
• W2800647235 type Work @default.
• W2800647235 sameAs 2800647235 @default.
• W2800647235 citedByCount "11" @default.
• W2800647235 countsByYear W28006472352019 @default.
• W2800647235 countsByYear W28006472352020 @default.
• W2800647235 countsByYear W28006472352021 @default.
• W2800647235 countsByYear W28006472352022 @default.
• W2800647235 crossrefType "journal-article" @default.
• W2800647235 hasAuthorship W2800647235A5003069482 @default.
• W2800647235 hasAuthorship W2800647235A5003581995 @default.
• W2800647235 hasAuthorship W2800647235A5006705594 @default.
• W2800647235 hasAuthorship W2800647235A5014153145 @default.
• W2800647235 hasAuthorship W2800647235A5015917994 @default.
• W2800647235 hasAuthorship W2800647235A5027749653 @default.
• W2800647235 hasAuthorship W2800647235A5028727344 @default.
• W2800647235 hasAuthorship W2800647235A5033063736 @default.
• W2800647235 hasAuthorship W2800647235A5033841824 @default.
• W2800647235 hasAuthorship W2800647235A5037283048 @default.
• W2800647235 hasAuthorship W2800647235A5040437868 @default.
• W2800647235 hasAuthorship W2800647235A5046049357 @default.
• W2800647235 hasAuthorship W2800647235A5047984145 @default.
• W2800647235 hasAuthorship W2800647235A5051605599 @default.
• W2800647235 hasAuthorship W2800647235A5053019069 @default.
• W2800647235 hasAuthorship W2800647235A5058765211 @default.
• W2800647235 hasAuthorship W2800647235A5061694042 @default.
• W2800647235 hasAuthorship W2800647235A5066826766 @default.
• W2800647235 hasAuthorship W2800647235A5082867129 @default.
• W2800647235 hasAuthorship W2800647235A5084858618 @default.
• W2800647235 hasAuthorship W2800647235A5085255418 @default.
• W2800647235 hasAuthorship W2800647235A5086292280 @default.
• W2800647235 hasAuthorship W2800647235A5091740511 @default.
• W2800647235 hasBestOaLocation W28006472351 @default.
• W2800647235 hasConcept C126322002 @default.
• W2800647235 hasConcept C128057223 @default.
• W2800647235 hasConcept C141071460 @default.
• W2800647235 hasConcept C2776694085 @default.
• W2800647235 hasConcept C2776755627 @default.
• W2800647235 hasConcept C2776995267 @default.
• W2800647235 hasConcept C2778720950 @default.
• W2800647235 hasConcept C2779338263 @default.
• W2800647235 hasConcept C2779429289 @default.
• W2800647235 hasConcept C2780252810 @default.
• W2800647235 hasConcept C2780653079 @default.
• W2800647235 hasConcept C2781146716 @default.
• W2800647235 hasConcept C2911091166 @default.
• W2800647235 hasConcept C71924100 @default.
• W2800647235 hasConcept C90924648 @default.
• W2800647235 hasConceptScore W2800647235C126322002 @default.
• W2800647235 hasConceptScore W2800647235C128057223 @default.
• W2800647235 hasConceptScore W2800647235C141071460 @default.
• W2800647235 hasConceptScore W2800647235C2776694085 @default.

• next